Telix announces first patient enrolled in 'ProstACT TARGET' study

Latest News

Telix Pharmaceuticals (ASX:TLX) and GenesisCare, the largest provider of integrated cancer care in Australia, have announced that a first patient has been enrolled in the Phase 2 ProstACT TARGET study of prostate cancer antibody therapy candidate TLX591.

The Telix candidate is being studied in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial treatment for prostate cancer.

Telix said its ProstACT therapeutic program is evaluating the efficacy of its TLX591 in various stages of prostate cancer, from the first recurrence to advanced metastatic disease. It said the primary focus of the ProstACT series of studies is to complete the Phase 3 ProstACT GLOBAL study in a second-line setting in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on first-line novel androgen agents.

The TARGET study is exploring the potential of TLX591 in combination with external radiation in patients at an earlier stage in their prostate cancer.

The study is seeking to enrol 50 patients across multiple Australian sites. The first patient has been enrolled at GenesisCare’s cancer centre at the St John of God Hospital Murdoch campus in Western Australia. 

The third concurrent study in the ProstACT program, ProstACT SELECT, is a theranostic Phase I radiogenomics study to demonstrate the utility of Telix’s imaging agent Illuccix.

Principal Investigator for the ProstACT TARGET study and GenesisCare Group medical director (Theranostics), Professor Nat Lenzo, said, “I’m excited to commence this important study that builds on the momentum of ProstACT SELECT. With previous studies having confirmed the preliminary efficacy and safety profile of TLX591, GenesisCare is pleased to partner with Telix to further their therapeutic antibody-based program, which has potential to improve health outcomes for thousands of men living with prostate cancer in Australia and worldwide.”

Telix chief medical officer Dr Colin Hayward added, “Enrolling a first patient in the ProstACT TARGET study is a significant milestone in Telix’s overall clinical mission to support men with prostate cancer at every step in their journey with a PSMA antibody approach to targeted radiation therapy. Alongside ProstACT SELECT, this program will add value and clinical insight to Telix’s antibody therapy candidate TLX591, as we progress global regulatory submissions for the ProstACT GLOBAL Phase III study. We wish to express our gratitude to Professor Nat Lenzo and his clinical team, as well as the patients who will contribute to the study.”